Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.66 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | ACHE | P22303 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 2/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.59 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.59 |
| ▸ | HTR3B | O95264 | 1/20 | 0.59 |
| ▸ | MPO | P05164 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.59 |
| ▸ | DRD4 | P21917 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Declopramide SCHEMBL30719968 | 1.00 | LMNA (0.66) | LMNAALDH1A1SLC22A1SLC22A2TSHR | |
| Declopramide SCHEMBL6436822 | 0.99 | LMNA (0.67) | LMNAALDH1A1SLC22A1SLC22A2TSHR | |
| Declopramide SCHEMBL5925509 | 0.96 | ALDH1A1 (0.61) | LMNAALDH1A1SLC22A1SLC22A2TSHR | |
| SCHEMBL18768840 | 0.87 | HPGD (0.63) | LMNAALDH1A1SLC22A1SLC22A2TSHR | |
| SCHEMBL2956109 | 0.87 | ALDH1A1 (0.71) | LMNAALDH1A1SLC22A1SLC22A2TSHR | |
| SCHEMBL3435195 | 0.86 | LMNA (0.52) | LMNAALDH1A1SLC22A1SLC22A2TSHR | |
| SCHEMBL12886918 | 0.85 | ALDH1A1 (0.68) | LMNAALDH1A1SLC22A1SLC22A2TSHR | |
| SCHEMBL5924476 | 0.85 | ALDH1A1 (0.68) | LMNAALDH1A1SLC22A1SLC22A2TSHR | |
| SCHEMBL10079549 | 0.84 | SMN1; SMN2 (0.56) | LMNAALDH1A1TSHRCYP1A2CYP2D6 | |
| SCHEMBL3435778 | 0.82 | SMN1; SMN2 (0.60) | LMNAALDH1A1TSHRKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 298 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250259704-A1 | SYSTEMS AND METHODS FOR CELL-FREE ITERATIVE SITE SATURATION MUTAGENESIS AND ITS APPLICATION FOR THE DIRECTED EVOLUTION OF ENZYMES CATALYZING UNNATURAL REACTIONS | U.S. DEPARTMENT OF ENERGY | 2025-08-14 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2023250524-A1 | SYSTEMS AND METHODS FOR CELL-FREE ITERATIVE SITE SATURATION MUTAGENESIS AND ITS APPLICATION FOR THE DIRECTED EVOLUTION OF ENZYMES CATALYZING UNNATURAL REACTIONS | NORTHWESTERN UNIVERSITY (US) | 2023-12-28 | — | — | WO | claimed |
| EP-2459227-B1 | Prodrugs containing an aromatic amine connected by an amide bond to a carrier | ASCENDIS PHARMA AS (DK) | 2021-03-17 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20120156260-A1 | Prodrugs Containing an Aromatic Amine Connected By an Amido Bond to a Linker | ASCENDIS PHARMA A/S (DK) | 2012-06-21 | — | — | US | claimed |
| EP-2459227-A1 | PRODRUGS CONTAINING AN AROMATIC AMINE CONNECTED BY AN AMIDO BOND TO A LINKER | Ascendis Pharma A/S (DK) | 2012-06-06 | — | — | EP | claimed |
| WO-2011012722-A1 | PRODRUGS CONTAINING AN AROMATIC AMINE CONNECTED BY AN AMIDO BOND TO A LINKER | ASCENDIS PHARMA AS (DK) | 2011-02-03 | — | — | WO | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| WO-2009045504-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER AND MODULATING SIGNAL TRANSDUCTION AND METABOLISM PATHWAYS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-04-09 | — | — | WO | claimed |
| EP-1393277-A1 | USE OF NFKB INHIBITORS TO TREAT DRY EYE DISORDERS | Alcon, Inc. (CH) | 2004-03-03 | — | — | EP | claimed |
| US-6696453-B2 | ADMINISTERING NF- KAPPA B INHIBITORS FOR THERAPY OF DRY EYES | ALCON, INC. (CH) | 2004-02-24 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| WO-2002095704-A9 | USE OF NF-KAPPA-B INHIBITORS TO TREAT DRY EYE DISORDERS | ALCON INC (CH) | 2003-02-27 | — | — | WO | claimed |
| US-20030008854-A1 | Use of NF-kappabeta inhibitors to treat dry eye disorders | ALCON, INC. | 2003-01-09 | — | — | US | claimed |
| WO-2002095393-A2 | DRUG EVOLUTION: DRUG DESIGN AT HOT SPOTS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2002-11-28 | — | — | WO | claimed |
| WO-2002095704-A1 | USE OF NF-KAPPA-B INHIBITORS TO TREAT DRY EYE DISORDERS | ALCON, INC. (CH) | 2002-11-28 | — | — | WO | claimed |
| EP-0927030-A4 | USE OF ARYL N-SUBSTITUTED CARBOXAMIDES TO KILL TUMORS | OXIGENE INC (US) | 2000-01-26 | — | — | EP | claimed |
| EP-0927030-A1 | USE OF ARYL N-SUBSTITUTED CARBOXAMIDES TO KILL TUMORS | OXIGENE, INC. (US) | 1999-07-07 | — | — | EP | claimed |
| WO-1997032576-A1 | USE OF ARYL N-SUBSTITUTED CARBOXAMIDES TO KILL TUMORS | OXIGENE, INC. (US) | 1997-09-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156260-A1 | Prodrugs Containing an Aromatic Amine Connected By an Amido Bond to a Linker | DAO, DNPEP, DDC | LMNA 759/4885ALDH1A1 899/4885SLC22A1 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.